Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4358

Sort by

Sort Order Select

Journal Articles

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Blood (2021) 138 (3): 273–282.

https://doi.org/10.1182/blood.2021011281

Published: 2021

Journal Articles

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

Blood (2021) 137 (23): 3291–3305.

https://doi.org/10.1182/blood.2020009362

Published: 2021

Includes: Supplemental data

Journal Articles

BAD(FF) to the bone: misbehaving B cells in cGVHD

Nataliya Prokopenko Buxbaum

Blood (2021) 137 (18): 2426–2427.

https://doi.org/10.1182/blood.2021011008

Published: 2021

Journal Articles

BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation

Wei Jia, Jonathan C. Poe, Hsuan Su, Sarah Anand, Glenn K. Matsushima, Jeffrey C. Rathmell, Ivan Maillard, Vedran Radojcic, Kazuhiro Imai, Nancy J. Reyes, Diana M. Cardona, Zhiguo Li, Amy N. Suthers, Itaevia M. Curry-Chisolm, Rachel A. DiCioccio, Daniel R. Saban, Benny J. Chen, Nelson J. Chao, Stefanie Sarantopoulos

Blood (2021) 137 (18): 2544–2557.

https://doi.org/10.1182/blood.2020008040

Published: 2021

Includes: Supplemental data

Journal Articles

Sclerotic chronic GVHD: you may WANT to block WNT

Stephanie J. Lee

Blood (2021) 137 (17): 2284.

https://doi.org/10.1182/blood.2021010953

Published: 2021

Journal Articles

Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease

Blood (2021) 137 (17): 2403–2416.

https://doi.org/10.1182/blood.2020008720

Published: 2021

Includes: Supplemental data

Journal Articles

An ounce of which prevention is worth a…?

Joerg Halter, Jakob Passweg

Blood (2021) 137 (14): 1852–1853.

https://doi.org/10.1182/blood.2021010688

Published: 2021

Journal Articles

Signaling through the type 2 cannabinoid receptor regulates the severity of acute and chronic graft-versus-host disease

Cheng Yin Yuan, Vivian Zhou, Garrett Sauber, Todd Stollenwerk, Richard Komorowski, Alicia López, Rosa María Tolón, Julian Romero, Cecilia J. Hillard, William R. Drobyski

Blood (2021) 137 (9): 1241–1255.

https://doi.org/10.1182/blood.2020004871

Published: 2021

Includes: Supplemental data

Journal Articles

Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults

Blood (2020) 136 (10): 1201–1211.

https://doi.org/10.1182/blood.2020005590

Published: 2020

Includes: Supplemental data

Journal Articles

Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance

Carlijn Voermans, Mette D. Hazenberg

Blood (2020) 136 (4): 410–417.

https://doi.org/10.1182/blood.2019000951

Published: 2020

Journal Articles

The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD

Blood (2020) 136 (1): 130–136.

https://doi.org/10.1182/blood.2019003369

Published: 2020

Includes: Supplemental data

Journal Articles

Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies

Blood (2020) 135 (15): 1287–1298.

https://doi.org/10.1182/blood.2019003186

Published: 2020

Includes: Supplemental data

Journal Articles

Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease

Blood (2020) 135 (1): 28–40.

https://doi.org/10.1182/blood.2019000032

Published: 2020

Includes: Supplemental data

Journal Articles

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Denis Claude Roy, MD, Irwin Walker, MBBS, FRCPC, Johan A. Maertens, MD PhD, Philippe Lewalle, Eduardo Olavarria, MD PhD, Yves Beguin, MD PhD, Dominik Selleslag, MD, Eva Maria Wagner, MD, Halvard Bönig, Gerard Bos, MD PhD, Stephan Mielke, MD

Blood (2019) 134 (Supplement_1): 592.

https://doi.org/10.1182/blood-2019-128344

Published: 2019

Journal Articles

Microrna-31 Regulates T-Cell Metabolism Via HIF1α and Promotes Effector Function

Yongxia Wu, PhD MD, Mengmeng Zhang, MD, David Bastian, Mohammed Hanief Sofi, PhD MS, Steven Douglas Schutt, BS, Hee-Jin Choi, PhD, Corey Mealer, Hung D Nguyen, PhD, Linlu Tian, Xue-Zhong Yu, MD MS

Blood (2019) 134 (Supplement_1): 623.

https://doi.org/10.1182/blood-2019-131587

Published: 2019

Journal Articles

Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)

Elizabeth Stenger, MD, Rachel Phelan, MDMPH, Bronwen E. Shaw, MD PhD, Minoo Battiwalla, MD, Stephanie Bo-Subait, MPH, Ruta Brazauskas, PhD, David K. Buchbinder, MD MSHS, Betty K. Hamilton, MD, Shalini Shenoy, MD, Lakshmanan Krishnamurti, MD

Blood (2019) 134 (Supplement_1): 697.

https://doi.org/10.1182/blood-2019-128797

Published: 2019

Journal Articles

Longitudinal Trajectory of Frailty in Blood or Marrow Transplant (BMT) Survivors - a BMT Survivor Study (BMTSS)

Mukta Arora, MD, Yanjun Chen, MS, Jessica Wu, MPH, Lindsey Hageman, MPH, Emily Ness, MPH, Michelle Kung, MA, Liton F. Francisco, BS, Alysia Bosworth, BA, Daniel J. Weisdorf, MD, Stephen J Forman, MD, Wendy Landier, PhD CRNP, Merve - Pamukçuoğlu, MD, Saro H. Armenian, DO, MPH, Lennie Wong, PhD, Smita Bhatia, MDMPH

Blood (2019) 134 (Supplement_1): 699.

https://doi.org/10.1182/blood-2019-123344

Published: 2019

Journal Articles

Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT

Claire Burney, MBBS, Stephen Robinson, MBBS, PhD BSc, Ariane Boumendil, PhD, Hervé Finel, Irma Khvedelidze, Hannah Hunter, MB,FRCPath,MRCP, Xavier Poire, Bruno Lioure, MD, Karl S Peggs, Robin Foà, MD, Srinivas Pillai, MBBS,MD MRCP, FRCPath, Tom Van Meerten, MD PhD, Juan Jose Bargay, Christoph Schmid, MD, Vergote Vibeke, Arnold Ganser, MD, Luca Castagna, MD, Ghulam J. Mufti, Silvia Montoto, MD

Blood (2019) 134 (Supplement_1): 701.

https://doi.org/10.1182/blood-2019-123442

Published: 2019

Journal Articles

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Haris Ali, MD, David Snyder, MD, Tracy Stiller, MS, Timothy Synold, PhD, Saloomeh Mokhtari, Joycelynne Palmer, PhD, Amandeep Salhotra, MD, Vinod A. Pullarkat, MD, Ji-lian Cai, MD, Stephen J Forman, MD, Matthew Mei, MD, Ryotaro Nakamura, MD

Blood (2019) 134 (Supplement_1): 669.

https://doi.org/10.1182/blood-2019-127445

Published: 2019

Journal Articles

Bone Marrow Versus Mobilized Peripheral Blood Stem Cells for Non T Depleted Haploidentical Transplantations with Post Transplantation Cyclophosphamide in Acute Lymphoblastic Leukemia: On Behalf of the ALWP of the EBMT

Arnon Nagler, MD MSc, Myriam Labopin, MD, Emanuele Angelucci, MD, Yener Koc, MD, Mutlu Arat, MD, Pietro Pioltelli, MD, Simona Sica, MD, Zafer Gülbas, MD, Johanna Tischer, MD, Paolo Bernasconi, MD, Jiri Pavlu, MDMRCP,FRCPath, Gerard Socie, MD PhD, Didier Blaise, MD PhD, Luigi Rigacci, MD, Massimo Martino, MD, José Luis Díez-Martín, MD PhD, Zinaida Peric, MD PhD, Sebastian Giebel, MD PhD, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 589.

https://doi.org/10.1182/blood-2019-121644

Published: 2019

NARROW

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

BAD(FF) to the bone: misbehaving B cells in cGVHD

BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation

Sclerotic chronic GVHD: you may WANT to block WNT

Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease

An ounce of which prevention is worth a…?

Signaling through the type 2 cannabinoid receptor regulates the severity of acute and chronic graft-versus-host disease

Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults

Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance

The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD

Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies

Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Microrna-31 Regulates T-Cell Metabolism Via HIF1α and Promotes Effector Function

Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)

Longitudinal Trajectory of Frailty in Blood or Marrow Transplant (BMT) Survivors - a BMT Survivor Study (BMTSS)

Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Bone Marrow Versus Mobilized Peripheral Blood Stem Cells for Non T Depleted Haploidentical Transplantations with Post Transplantation Cyclophosphamide in Acute Lymphoblastic Leukemia: On Behalf of the ALWP of the EBMT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only